UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004
Executive Summary
UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004
You may also be interested in...
Lunesta, Crestor, Sanctura Among New Products In UnitedHealth Registry
Sepracor's insomnia agent Lunesta, AstraZeneca's statin Crestor and Indevus' overactive bladder therapy Sanctura are among the new products to be included in UnitedHealth's postmarketing surveillance drug registry
Lunesta, Crestor, Sanctura Among New Products In UnitedHealth Registry
Sepracor's insomnia agent Lunesta, AstraZeneca's statin Crestor and Indevus' overactive bladder therapy Sanctura are among the new products to be included in UnitedHealth's postmarketing surveillance drug registry
Medicare Rx Data May Be Difficult To Interpret, Merck Exec Cautions
Drawing conclusions about drug safety and outcomes from Medicare prescription drug data needs to be done with caution, Merck VP-Outcomes Research & Management Marc Berger told a Centers for Medicare & Medicaid Services "Open Door Forum" June 13